IL295938A - Therapeutic uses of macrocyclic compounds - Google Patents
Therapeutic uses of macrocyclic compoundsInfo
- Publication number
- IL295938A IL295938A IL295938A IL29593822A IL295938A IL 295938 A IL295938 A IL 295938A IL 295938 A IL295938 A IL 295938A IL 29593822 A IL29593822 A IL 29593822A IL 295938 A IL295938 A IL 295938A
- Authority
- IL
- Israel
- Prior art keywords
- cancer
- carcinoma
- met
- compound
- alkyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062984159P | 2020-03-02 | 2020-03-02 | |
| PCT/US2021/020255 WO2021178296A1 (en) | 2020-03-02 | 2021-03-01 | Therapeutic uses of macrocyclic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL295938A true IL295938A (en) | 2022-10-01 |
Family
ID=77613771
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL295938A IL295938A (en) | 2020-03-02 | 2021-03-01 | Therapeutic uses of macrocyclic compounds |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20250262216A1 (https=) |
| EP (1) | EP4114530A4 (https=) |
| JP (1) | JP2023515687A (https=) |
| KR (1) | KR20230022151A (https=) |
| CN (1) | CN115397514A (https=) |
| AU (1) | AU2021229457A1 (https=) |
| BR (1) | BR112022017425A2 (https=) |
| CA (1) | CA3174455A1 (https=) |
| IL (1) | IL295938A (https=) |
| MX (1) | MX2022010945A (https=) |
| WO (1) | WO2021178296A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111902417B (zh) | 2018-04-25 | 2023-07-28 | 北京普祺医药科技股份有限公司 | 一种二芳基巨环化合物、药物组合物以及其用途 |
| US20240132517A1 (en) * | 2021-02-10 | 2024-04-25 | Goharmony Therapeutics (Shenzhen) Co., Ltd. | Macrocyclic compound, pharmaceutical composition, and use thereof |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS49779B (sr) * | 1998-01-12 | 2008-06-05 | Glaxo Group Limited, | Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze |
| ES2933350T3 (es) * | 2014-01-24 | 2023-02-06 | Turning Point Therapeutics Inc | Macrociclos de diarilo como moduladores de proteína quinasas |
| RU2765181C2 (ru) * | 2015-07-06 | 2022-01-26 | Тёрнинг Поинт Терапьютикс, Инк. | Полиморфная форма диарильного макроцикла |
| US10689400B2 (en) * | 2016-07-28 | 2020-06-23 | Turning Point Therapeutics, Inc. | Macrocycle kinase inhibitors |
| CN111182903A (zh) * | 2017-07-28 | 2020-05-19 | 特普医药公司 | 巨环化合物及其用途 |
| CN114423762B (zh) * | 2019-09-30 | 2024-03-29 | 浙江海正药业股份有限公司 | 大环类衍生物及其制备方法和用途 |
-
2021
- 2021-03-01 EP EP21764224.8A patent/EP4114530A4/en not_active Withdrawn
- 2021-03-01 JP JP2022552626A patent/JP2023515687A/ja active Pending
- 2021-03-01 CN CN202180023879.XA patent/CN115397514A/zh active Pending
- 2021-03-01 CA CA3174455A patent/CA3174455A1/en active Pending
- 2021-03-01 BR BR112022017425A patent/BR112022017425A2/pt unknown
- 2021-03-01 WO PCT/US2021/020255 patent/WO2021178296A1/en not_active Ceased
- 2021-03-01 MX MX2022010945A patent/MX2022010945A/es unknown
- 2021-03-01 KR KR1020227034099A patent/KR20230022151A/ko active Pending
- 2021-03-01 IL IL295938A patent/IL295938A/en unknown
- 2021-03-01 AU AU2021229457A patent/AU2021229457A1/en not_active Abandoned
- 2021-03-01 US US17/905,503 patent/US20250262216A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250262216A1 (en) | 2025-08-21 |
| AU2021229457A1 (en) | 2022-10-20 |
| CN115397514A (zh) | 2022-11-25 |
| BR112022017425A2 (pt) | 2022-11-29 |
| EP4114530A4 (en) | 2024-04-17 |
| MX2022010945A (es) | 2022-10-07 |
| CA3174455A1 (en) | 2021-09-10 |
| WO2021178296A1 (en) | 2021-09-10 |
| KR20230022151A (ko) | 2023-02-14 |
| JP2023515687A (ja) | 2023-04-13 |
| EP4114530A1 (en) | 2023-01-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12310968B2 (en) | Chiral diaryl macrocycles and uses thereof | |
| IL267992B2 (en) | Combination therapy involving macrocyclic diaryl compounds | |
| US20130004481A1 (en) | Anticancer therapy | |
| EP3585389A1 (en) | Treatment of egfr-driven cancer with fewer side effects | |
| US8937095B2 (en) | Anticancer compounds | |
| IL311387A (en) | Methods of treating solid tumor using heteroaromatic macrocyclic ether compounds | |
| WO2019165473A1 (en) | Methods of treatment of cancer comprising cdc7 inhibitors | |
| IL295938A (en) | Therapeutic uses of macrocyclic compounds | |
| IL278596B1 (en) | RAS oncoprotein inhibitors, methods for preparing and methods for using them | |
| WO2026015740A1 (en) | Macrocyclic ras inhibitors | |
| HK40097088A (zh) | 作为ras抑制剂以治疗癌症的吲哚衍生物 | |
| BR112024002063B1 (pt) | Compostos que inibem isoforma alfa de pi3k, composições que o compreendem, usos dos mesmos, e combinações | |
| HK40076319A (en) | Ras inhibitors |